Anti-β Galactosidase Antibody, clone 2C15 ZooMAb® Rabbit Monoclonal

Description

• General description: We are committed to bringing you greener alternative products, which adhere to one or more of The 12 Principles of Green Chemistry.This antibody is Preservative-free, produced without the harm or sacrifice of animals and exceptionally stable to allow for ambient shipping and storage if needed and thus aligns with "Waste Prevention", "Designing Safer Chemicals" and "Design for Energy Efficiency". Click here for more information.
• Specificity: Clone 2C15 is a ZooMAb® Rabbit recombinant monoclonal antibody that specifically detects β-Galactosidase. It targets an epitope within 22 amino acids from the N-terminal region.
• Immunogen: KLH-conjugated linear peptide corresponding to 22 amino acids from the N-terminal region of human β-Galactosidase.
• Application: Quality Control TestingEvaluated by Western Blotting in HepG2 cell lysates.Western Blotting Analysis: A 1:10,000 dilution of this antibody detected β Galactosidase in HepG2 cell lysates.Tested ApplicationsWestern Blotting Analysis: A 1:1,000 dilution from a representative lot detected β Galactosidase in COS-7 cell lysate.Affinity Binding Assay: A representative lot of this antibody bound Beta Galactosidase peptide with a KD of 3.5 x 10-7 in an affinity binding assay.Immunohistochemistry (Paraffin) Analysis: A 1:1,000 dilution from a representative lot detected β Galactosidase in human liver tissue sections.Immunocytochemistry Analysis: A 1:100 dilution from a representative lot detected β Galactosidase in HepG2 cells.Note: Actual optimal working dilutions must be determined by end user as specimens, and experimental conditions may vary with the end user.
• Target description: Beta-galactosidase (UniProt: P16278; also known as EC:3.2.1.23, Acid beta-galactosidase, Lactase, Elastin receptor 1) is encoded by the GLB1 (also known as ELNR1) gene (Gene ID: 2720) in human. The β-galactosidase is a highly glycosylated, homodimeric enzyme that cleaves β-linked terminal galactosyl residues from gangliosides, glycoproteins, and glycosaminoglycans. It is also reported to form a tetrameric structure. It is abundantly expressed in placenta and in testis. It displays strict specificity at the galactosyl position but can hydrolyze β-D-galactopyranosides with a wide variety of aglycons. Human β-galactosidase is synthesized with a 23 amino acid secretion signal and the enzyme is synthesized as an 88 kDa precursor that is transferred to the lysosomal compartment where it is processed to a 64 kDa mature enzyme by proteolytic cleavage of the C-terminal region. The C-terminal fragment is reported to remain associated with the N-terminal fragment. In human β-galactosidase, glutamic acid 268 is identified as the catalytic nucleophile, and glutamic acid 188 is a candidate for the acid/base catalyst. These residues are located in the fourth and seventh β-strand of the TIM barrel domain, respectively. Three isoforms of β-galactosidase have been described that are produced by alternative splicing.  Isoform 1 is present in lysosomes and isoform 2 is detected in the cytoplasm and in perinuclear region. Isoform 2 lacks β-galactosidase catalytic activity but it plays a functional role in the formation of extracellular elastic fibers and in the development of connective tissue.  Defects in and dysfunction of β-galactosidase  and mutations in GLB1 gene have been linked to metabolic storage disorders, such a GM1 gangliosidosis, a severe neurological disease. This ZooMAb® recombinant monoclonal antibody, generated by our propriety technology, offers significantly enhanced specificity, affinity, reproducibility, and stability over conventional monoclonals. (Ref.: Ohtu, U., et al. (2012). J. Biol. Chem. 287(3); 1801-1812; Caciotti, A., et al. (2005). Hum. Mutat. 25(3); 285-292).
• Physical form: Purified recombinant rabbit monoclonal antibody IgG, lyophilized in PBS, 5% Trehalose, normal appearance a coarse or translucent resin. The PBS/trehalose components in the ZooMAb formulation can have the appearance of a semi-solid (bead like gel) after lyophilization. This is a normal phenomenon. Please follow the recommended reconstitution procedure in the data sheet to dissolve the semi-solid, bead-like, gel-appearing material. The resulting antibody solution is completely stable and functional as proven by full functional testing. Contains no biocide or preservatives, such as azide, or any animal by-products. Larger pack sizes provided as multiples of 25 µL.
• Reconstitution: 0.3 mg/mL after reconstitution at 25 µL per vial. Please refer to guidance on suggested starting dilutions and/or titers per application and sample type.
• Storage and Stability: Recommend storage of lyophilized product at 2-8°C; Before reconstitution, micro-centrifuge vials briefly to spin down material to bottom of the vial; Reconstitute each vial by adding 25 µL of filtered lab grade water or PBS; Reconstituted antibodies can be stored at 2-8°C, or -20°C for long term storage. Avoid repeated freeze-thaws.
• Legal Information: ZooMAb is a registered trademark of Merck KGaA, Darmstadt, Germany
• Disclaimer: Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.